

Investigating the relationship between possible assessment tools (visual analogue scale, Tampa Scale of Kinesiophobia and Brief pain inventory) for SCD pain

¹Lawrence Ababio Boateng, ²Eugenia V. Asare, ¹Robert Reeks, ¹Grace K. Ababio

¹University of Ghana Medical School, Medical Biochemistry, Korle-Bu, Accra, Ghana

²Ghana Institute of Clinical Genetics (sickle cell clinic), Korle-Bu, Accra, Ghana

Abstract

Background: Pain is among the most frequent consequences of sickle cell disease (SCD) and this is of global health concern. Here, we present a relationship between three (3) possible pain assessment tools to guide and provide insight into SCD pain.

Aim: To investigate the plausible relationship between three assessment tools (visual analogue scale, Tampa Scale of Kinesiophobia and Brief pain inventory) that could be used for SCD pain

Methodology: The case-control study was located at the Ghana Institute of Clinical Genetics (sickle cell clinic) adult. The controls consisted of students of University of Ghana Medical School (UGMS) in Korle-Bu. After obtaining ethical clearance from College of Health Sciences (CHS-Et/M.1-P5.12/2023-2024), a validated pain assessment questionnaires were used for data collection. Four (4) mL of blood was collected in EDTA tube for full blood count and Hemoglobinopathy cellulose acetate electrophoresis. The data analysis was done utilizing the Statistical Package for the Social Science (SPSS) version 21 and Microsoft Excel 2016.

Results: There was a paradigm shift when tampa scale of kinesophobia (TSK) was included in the statistical analysis between visual analogue scale (VA) and Brief pain inventory (BPI) scores in SCD subjects. General characteristics, gender-matched and age-matched data had statistical significance in age, BMI, heart rate, Temperature, BPI PI, BPI PS, VA PR, VA PI, and some selected hematological parameters during ANOVA in the three groups. SS subjects appeared relatively lean and showed an increase in fear of musculoskeletal activities avoidance.

Conclusion: There was strong association between BPI, VA and TSK with a p-value of 0.000 in SCD subjects.

Keywords: Pain, Sickle cell disease, visual analogue scale, Tampa Scale of Kinesiophobia, Brief pain inventory (BPI)

Introduction

Recurrent pain is the number one cause of Sickle cell disease (SCD) related hospitalizations [1] associated with low quality of life [2], depression, functional disability, increased somatic burden and anxiety [3].

In Ghana, SCD affects 2% of all newborns annually [4]. Despite the fact that SCD can cause intravascular and extravascular hemolysis [5], it is actually characterized by normocytic intrinsic hemolytic anemia [6] brought on by defective hemoglobin and or mutation at the sixth position of beta globin gene [7]. SCD is therefore, hereditary with its hallmark being vaso occlusive painful crisis [8].

The painful experience is multidimensionally subjective, depicting a limitation in the already established neurobiological mechanism of pain and the transition from acute to chronic pain [9]. Apart from International Association for the Study of Pain (IASP) definition of pain as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage [10], it is now evident that pain may be reported in the absence of tissue damage or any pathophysiological cause [11].

Here, we sought to investigate the plausible relationship between three (3) possible assessment tools for SCD pain, namely, the visual analogue scale (VAS), Tampa Scale of Kinesiophobia (TSK) and Brief pain inventory (BPI). VAS [12] ask SCD patients to rate pain intensity on a spectrum, either choosing a single number or subject's facial expression at the time the assessment is completed. Since it remains possible to generate interindividual variability in VAS pain-intensity scores, this research adds on with TSK and BPI. BPI [13] assesses pain severity and impact of pain on the daily activities of subjects experiencing SCD pain, while TSK [14] quantifies fear associated with movement which may be due to SCD pain. We thus anticipated that, subjects experiencing vaso occlusive crisis, might have higher TSK scores as well as higher BPI scores, hence, the focus.

Aim: To assess the visual analogue scale, Tampa Scale of Kinesiophobia (TSK) and Brief pain inventory (BPI) on pain severity in study subjects.

Methodology

Study Design, Study Site, Study Population

This was a case-control study located at the Ghana Institute of Clinical Genetics (sickle cell clinic) in the Ablekuma South Metropolitan District of Accra. The control group were students of University of Ghana Medical School (UGMS) in Korle-Bu, Accra, Ghana.

Inclusion Criteria

- Any sickle cell disease patient above age 13 years were included irrespective of his/her genotype.
- Ballas criteria for steady state was strictly followed [15].
- Patients with SCD-related chronic complications were added in this study.

Exclusion Criteria

- Patients who had a blood transfusion within the last 3 months and those who declined to respond to the questionnaire were excluded.

Sample Size Determination And Sampling Strategy

Cochran formula was used; $n = [z^2(p)(1-p)]/e^2$. At 95% confidence interval, $z = 1.96$, desired precision 'e' of 0.05, and SCD prevalence 'p' being 0.02, the minimum sample size was calculated.

On the field, a hundred and sixty – two (162) SCD cases were obtained, while the control population was 52 and these were matched for both age and gender, hence giving a total sample size of 214.

Sampling Strategy

Convenient sampling.

Data Collection, Tool And Methods

After obtaining ethical clearance from College of Health Sciences (CHS-Et/M.1-P5.12/2023-2024), pain severity assessment questionnaire and venous blood samples were obtained for analysis of full blood count and hemoglobin electrophoresis. These are briefly described below:

Visual analogue scale

This is a validated subjective assessment of pain. A 10cm line is used to represent the degree of pain. The zero mark is consistent with no pain whilst the 10 cm mark is consistent with the worst pain possible. Individuals were therefore required to grade their pain per this graduation.

Tampa scale of kinesiophobia

This is a 17-item questionnaire used to quantify fear associated with movement which may be due to pain. Individuals responding to the questionnaire record their responses based on the extent to which they agree with the statements. The degree of agreements ranges from strongly disagree, somewhat disagree, somewhat agree and strongly agree. These correspond to a score of 1, 2, 3 and 4 respectively.

Brief pain inventory

The brief pain inventory is a validated questionnaire used in the assessment of the severity and impact of pain on the daily activities of individuals with musculoskeletal diseases, malignancies and depression. It makes use of a rating scale ranging from 0 to 10 where 0 is consistent with no pain and 10 is consistent with pain as bad as you can imagine. Interference of activities is also assessed using a rating scale of 0 to 10 with 0 consistent with no pain and 10 consistent with complete interference.

Cellulose acetate electrophoresis

The experiment involved migrating hemoglobin protein dissolved in an alkaline buffer through an electric field using an electrophoresis tank and sample holder. Materials included an alkaline buffer, cellulose acetate membrane, chromatographic paper, and blotting paper. EDTA whole blood was processed to obtain red blood cells, washed, and placed on the marked cellulose acetate membrane. Electrophoretic run parameters were set, and hemoglobin migration was assessed by comparing it to a reference hemoglobinopathy.

Results

Socio-Demographics

The control group appeared younger than the study group. The mean age for the SCD group was 29.65 ± 12.20 (162) while the mean age for the control group was 22.73 ± 1.59 (52). The study group was predominately composed of females with 62.7% and 49.4% of the study population had tertiary level of education. While 82.5% of the study population were single, Christians formed the bulk (89.2%) of the study population. Majority of subjects in both SCD and controls never smoked.

General Characteristics

In analysis of variance, age, heart rate, BMI, Temperature, BPI PS, BPI PI, VA PI, VA PR and some selected hematological parameters were statistically significant when VOC and Steady state were compared, as well as, when control, VOC and Steady state were compared in Sickle cell patients (Table 1). A similar trend was also observed in age - matched analysis in SCD patients less than 30 years (*See appendix for Supplementary Tables 1a and 1b*).




Fig. 1 Cellulose acetate electrophoretogram for the hemoglobinopathy identified in this study

Visual Analogue Scale (Va), Tampa Scale Of Kinesiophobia (Tsk) And Brief Pain Inventory (Bpi) Scores

TSK analysis indicated that SS subjects showed much fear of avoidance in musculoskeletal activities (Tables 1; *Supplementary Tables 1b and 2b*). The Cronbach alpha in SCD TSK analysis was 0.643 and in controls, it was 0.594.

Table 1: General characteristics of study population

| | Control | | | Vasoocclusive Crisis (VOC) SCD cases | | | | p-value | Steady state SCD | | | | p-value | |
|--|----------------------------|----------------------------|---------|--------------------------------------|--------------------|-------------------|---------|---------|--------------------------|---------------------------|--------------------|-------------------|---------|--------------------|
| | AA ₍₃₉₎ | AS ₍₁₃₎ | p-value | SS ₍₃₆₎ | SC ₍₁₃₎ | SF ₍₂₎ | p-value | | VOC x controls | SS ₍₇₈₎ | SC ₍₃₁₎ | SF ₍₂₎ | p-value | Steady state x VOC |
| Gender | | | | | | | | | | | | | | |
| Male | 24 | 5 | | 12 | 5 | 2 | | | 30 | 11 | 1 | | | |
| Female | 15 | 8 | | 24 | 8 | 0 | | | 38 | 20 | 1 | | | |
| Age (years) | 22.77±1.61* | 22.62±1.56 | 0.771 | 28.26±9.28 | 15.21±33.78 | 28.50±14.85 | 0.107 | 0.049 | 28.77±11.28 | 32.71±5.73 | 20.50±3.54 | 0.202 | 0.022 | 0.001 |
| BMI (kg/m²) | 25.16±4.32 | 23.83±3.45 | 0.320 | 21.12±4.84 | 22.74±5.72 | 20.00±0.51 | 0.560 | 0.005 | 21.11±4.59 | 22.68±3.37 | 28.42±2.33 | 0.018 | 0.125 | 0.000 |
| SBP (mmHg) | 115.15±8.99 | 116.23±9.08 | 0.710 | 113.64±13.03 | 119.54±9.21 | 119.50±15.56 | 0.324 | 0.561 | 113.82±11.36 | 117.47±14.64 | 111.00±19.80 | 0.375 | 0.505 | 0.447 |
| DBP (mmHg) | 75.33±6.40 | 71.77±4.38 | 0.069 | 70.11±12.69 | 73.08±13.53 | 83.00±7.07 | 0.337 | 0.140 | 70.31±13.36 | 71.52±13.64 | 66.5±6.36 | 0.795 | 0.697 | 0.266 |
| HR (bpm) | 76.38±6.43 | 74.54±6.46 | 0.376 | 88.22±10.30 | 87.00±10.90 | 76.00±8.49 | 0.277 | 0.000 | 84.21±12.26 | 80.97±9.86 | 60.00±15.60 | 0.008 | 0.000 | 0.000 |
| Temp (°C) | 36.57±0.28 | 36.57±0.33 | 0.750 | 36.47±0.47 | 36.65±0.47 | 37.20±0.57 | 0.015 | 0.000 | 36.43±0.30 | 36.46±0.30 | 36.10±0.14 | 0.258 | 0.004 | 0.000 |
| BPI PS score | 0.26±0.91 | 0±0.00 | 0.311 | 4.90±1.90 | 5.13±1.43 | 4.50±2.40 | 0.884 | 0.000 | 1.79±2.01 | 2.81±2.17 | 2.25±3.18 | 0.072 | 0.000 | 0.000 |
| BPI PI score | 0.21±0.94 | 0±0.00 | 0.427 | 5.54±2.64 | 6.55±2.02 | 5.35±2.90 | 0.458 | 0.000 | 2.45±2.78 | 3.58±3.15 | 2.35±3.32 | 0.185 | 0.000 | 0.000 |
| TSK | 24.21±6.09 | 21.92±3.38 | 0.204 | 38.06±8.27 | 37.38±9.54 | 43.00±5.66 | 0.690 | 0.000 | 35.03±6.54 | 36.58±7.97 | 28.50±7.78 | 0.222 | 0.149 | 0.000 |
| VA PI | 0.44±1.67 | 0±0.00 | 0.350 | 6.39±1.92 | 7.77±1.23 | 6.00±2.83 | 0.06 | 0.000 | 1.58±2.45 | 1.80±2.41 | 2.00±2.83 | 0.895 | 0.000 | 0.000 |
| Visual analogue pain rating | 0.18±0.68 | 0±0.00 | 0.348 | 3.09±1.37 | 3.62±1.12 | 3.00±1.41 | 0.416 | 0.000 | 0.81±1.27 | 0.90±1.30 | 1.00±1.41 | 0.931 | 0.000 | 0.000 |
| Hb (g/dl) | 12.96±1.15 ₍₃₈₎ | 11.66±1.82 ₍₁₁₎ | 0.006 | 8.09±13.8 ₍₃₁₎ | 10.31±0.87 | | 0.000 | 0.000 | 7.99±135 ₍₆₂₎ | 10.50±134 ₍₃₀₎ | 12.40±3.54 | 0.000 | 0.000 | 0.000 |
| Rbc (10⁶/m³) | 4.88±0.88 | 4.62±0.50 | 0.356 | 2.76±0.62 | 3.90±0.47 | | 0.000 | 0.000 | 2.90±0.59 | 4.01±0.74 | 5.28±1.39 | 0.000 | 0.000 | 0.000 |
| Wbc (10³/mm³) | 4.14±2.46 | 3.18±1.80 | 0.236 | 14.76±14.20 | 7.87±2.50 | | 0.000 | 0.000 | 9.73±3.00 | 7.20±1.91 | 5.65±1.34 | 0.000 | 0.000 | 0.000 |
| Plt (10³/mm³) | 236.18±104.82 | 257.09±48.11 | 0.526 | 461.97±184.41 | 265.67±17.73 | | 0.000 | 0.000 | 401.39±136.03 | 279.37±78.71 | 195.00±49.50 | 0.000 | 0.000 | 0.000 |
| MCV (μm³) | 75.89±5.82 | 73.73±7.60 | 0.317 | 88.10±10.21 | 79.33±7.19 | | 0.000 | 0.000 | 81.93±10.64 | 78.47±8.44 | 72.30±0.71 | 0.147 | 0.012 | 0.000 |
| MCHC (g/dl) | 34.45±1.66 | 34.15±1.15 | 0.578 | 34.36±1.17 | 33.57±1.32 | | 0.056 | 0.266 | 28.06±4.13 | 33.48±2.14 | 32.25±0.35 | 0.000 | 0.000 | 0.000 |

Legend: *mean ± sd SCD = Sickle Cell Disease, VA PI = visual analogue pain intensity BPI PI score = Brief pain Inventory Pain Intensity BPI PS score = Brief pain Inventory Pain Severity BMI= Body mass Index SBP= Systolic Blood Pressure DBP= Diastolic Blood Pressure HR= Heart Rate TSK= Tampa Scale of Kinesiophobia VA PI= Visual Analogue Pain Intensity Hb= Haemoglobin rbc= Red blood cell wbc= White blood cell Plt= Platelet MCV= Mean corpuscular volume MCHC= Mean corpuscular haemoglobin concentration

Supplementary Table 1a: Age – matched characteristics of the study population

| | <30 years | | | | >30 years | |
|-------------------------------|--------------------|--------------------|---------|-------------------|-----------------------|---------------------|
| | Controls | | | VOC | VOC | |
| | AA ₍₃₉₎ | AS ₍₁₃₎ | p-value | SCD ₃₀ | Control x VOC p-value | SCD ₍₂₁₎ |
| Gender | | | | | | |
| Male | 24 | 5 | | 12 | | 7 |
| Female | 15 | 8 | | 18 | | 14 |
| BMI (kg/m²) | 25.16±4.33 | 23.83±3.45 | 0.320 | 20.00±4.54 | 0.000 | 23.77±4.86 |
| SBP (mmHg) | 115.15±8.99 | 112.23±9.07 | 0.316 | 112.70±11.40 | 0.498 | 119.24±13.08 |

| | | | | | | |
|--|----------------------------|----------------------------|-------|---------------------------|-------|--------------------------|
| DBP (mmHg) | 75.33±6.40 | 71.77±4.39 | 0.069 | 72.37±12.96 | 0.302 | 69.95±12.85 |
| HR (bpm) | 76.38±6.43 | 74.53±6.46 | 0.374 | 86.90±11.48 | 0.000 | 88.19±9.08 |
| Temp (°C) | 36.57±0.28 | 36.58±0.33 | 0.915 | 36.48±0.36 | 0.451 | 36.64±0.42 |
| BPI PS score | 0.26±1.31 | 0.00±0.00 | 0.480 | 5.15±2.67 | 0.000 | 4.66±1.59 |
| BPI PI score | 0.22±0.94 | 0.00±0.00 | 0.406 | 5.14±2.07 | 0.000 | 6.69±2.02 |
| TSK sum | 24.21±6.09 | 21.92±3.38 | 0.204 | 36.89±9.59 | 0.000 | 37.03±6.71 |
| VA PI | 0.44±1.67 | 0.00 | 0.350 | 6.70±1.80 | 0.000 | 6.76±2.00 |
| Visual analogue pain rating | 0.18±0.68 | 0.00 | 0.348 | 3.10±1.09 | 0.000 | 3.29±1.45 |
| Hb (g/dl) | 12.96±1.15 ₍₃₂₎ | 11.66±1.82 ₍₁₁₎ | 0.008 | 8.78±1.61 ₍₂₆₎ | 0.000 | 8.5±1.63 ₍₁₈₎ |
| Rbc (10⁶/mm³) | 4.88±0.88 | 4.62±0.49 | 0.359 | 3.10±0.80 | 0.000 | 2.97±0.78 |
| Wbc (10³/mm³) | 4.14±2.46 | 3.18±1.80 | 0.243 | 13.90±15.65 | 0.001 | 11.16±4.45 |
| Plt (10³/mm³) | 236.18±104.82 | 257.09±48.11 | 0.529 | 433.23±212.82 | 0.000 | 358.56±144.06 |
| MCV (µm³) | 75.89±5.82 | 73.73±7.60 | 0.332 | 85.92±9.3 | 0.000 | 85.72±11.56 |
| MCHC (g/dl) | 26.16±2.21 | 34.15±1.15 | 0.000 | 34.67±1.90 | 0.000 | 34.37±1.73 |

Supplementary Table 1b: Age – matched characteristics of the study population

| | <30 years | | | | >30 years | | | | | | |
|--|---------------------------|---------------------------|-------------------|---------|---------------------------|-------------------|---------|-------------------|-------------------|---------|---------------------------|
| | Steady state | | | VOC | Steady state | | | VOC | | | |
| | SS ₍₅₄₎ | SC ₍₁₇₎ | SF ₍₂₎ | p-value | SS ₍₂₃₎ | SC ₍₆₎ | p-value | SS ₍₇₎ | SC ₍₅₎ | p-value | SS ₍₁₃₎ |
| Gender | | | | | | | | | | | |
| Male | 21 | 3 | 1 | | 7 | 4 | | 1 | 1 | | 5 |
| Female | 33 | 14 | 1 | | 16 | 2 | | 6 | 4 | | 8 |
| BMI (kg/m²) | 21.16±2.69 | 20.99±2.53 | 28.42±2.83 | 0.001 | 19.93±4.82 | 20.14±4.16 | 0.923 | 33.40±1.37 | 26.17±2.73 | 0.000 | 23.39±4.17 |
| SBP (mmHg) | 113.4±3.54 | 110.0±0.57 | 111.0±0.80 | 0.499 | 111.96±11.84 | 116.33±10.67 | 0.420 | 117.57±15.24 | 123.00±18.92 | 0.735 | 116.7±14.91 |
| DBP (mmHg) | 70.06±11.01 | 67.00±11.33 | 66.50±15.56 | 0.575 | 70.74±2.17 | 77.67±16.43 | 0.262 | 64.85±14.00 | 81.80±16.10 | 0.080 | 69.00±13.99 |
| HR (bpm) | 84.83±8.77 | 81.51±9.21 | 66.00±15.56 | 0.012 | 87.61±1.90 | 87.00±9.08 | 0.908 | 84.57±5.71 | 83.00±6.48 | 0.666 | 89.31±6.90 |
| Temp (°C) | 36.46±0.31 | 36.50±0.34 | 36.10±0.14 | 0.244 | 36.44±0.34 | 36.57±0.45 | 0.441 | 36.40±0.11 | 36.42±0.41 | 0.908 | 36.52±0.25 |
| BPI PS score | 1.79±2.07 | 3.20±2.41 | 2.25±3.18 | 0.015 | 5.11±2.18 | 5.07±1.95 | 0.968 | 1.70±2.13 | 2.88±2.01 | 0.356 | 4.51±1.27 |
| BPI PI score | 2.45±2.82 | 3.63±3.63 | 2.35±3.32 | 0.375 | 4.59±2.69 | 5.80±2.71 | 0.468 | 1.94±2.57 | 3.60±2.93 | 0.322 | 6.68±2.29 |
| TSK sum | 34.44±6.64 | 34.06±6.51 | 28.50±7.78 | 0.463 | 38.21±9.35 | 34.67±10.93 | 0.431 | 36.29±6.55 | 39.00±5.15 | 0.460 | 37.77±6.26 |
| VA PI | 1.54±2.30 | 1.76±2.68 | 2.00±2.83 | 0.942 | 6.43±1.95 | 7.50±0.84 | 0.205 | 0.71±1.25 | 1.60±2.30 | 0.405 | 6.31±1.93 |
| Visual analogue pain rating | 0.72±1.16 | 0.71±1.10 | 1.00±1.41 | 0.944 | 3.13±1.32 | 3.00±0.89 | 0.822 | 0.43±0.79 | 1.40±2.19 | 0.000 | 2.92±1.50 |
| Hb (g/dl) | 8.07±1.44 ₍₄₂₎ | 9.95±1.41 ₍₁₆₎ | 12.40±3.54 | 0.000 | 8.22±1.32 ₍₂₀₎ | 10.67±0.94 | 0.000 | 7.42±1.16 | 11.00±0.84 | 0.262 | 7.86±1.52 ₍₁₁₎ |
| Rbc (10⁶/mm³) | 2.92±0.58 | 3.75±0.71 | 5.28±1.36 | 0.000 | 2.80±0.60 | 4.12±0.56 | 0.000 | 2.40±0.62 | 4.30±0.60 | 0.000 | 2.67±0.68 |
| Wbc (10³/mm³) | 10.06±3.05 | 7.22±1.83 | 5.65±1.34 | 0.001 | 16.10±7.29 | 6.58±2.03 | 0.197 | 10.00±3.02 | 5.66±1.53 | 0.004 | 12.33±5.18 |
| Plt (10³/mm³) | 416.1±2.39 | 296.3±1.83 | 195.0±0.49 | 0.000 | 492.70±254.94 | 235.00±7.41 | 0.024 | 481.67±18.625 | 250.00±53.03 | 0.018 | 406.09±129.86 |
| MCV (µm³) | 82.21±11.5 | 78.38±7.62 | 72.50±0.71 | 0.249 | 88.15±8.95 | 78.50±6.47 | 0.022 | 77.00±8.44 | 74.80±12.52 | 0.026 | 88.00±12.69 |

| | | | | | | | | | | | | |
|--------------------|----------------|----------------|----------------|-------|----------------|----------------|-------|------------|------------|--|-------|----------------|
| | 1 | | | | | | | | | | | |
| MCHC (g/dl) | 34.16 ±1.88 | 34.20 ±1.22 | 32.25 ±0.35 | 0.303 | 34.40±2 .67 | 33.37±1.2 8 | 0.366 | 33.68±1.70 | 34.70±1.13 | | 0.736 | 34.28±1.2 9 |

Even though visual analogue scale (VA) versus Brief pain inventory (BPI) scores in SCD subjects showed no statistical significance after analysis, the relationship had a paradigm shift when tampa scale of kinesophobia (TSK) was added (Table 2).

Table 2: Relationship between visual analogue scale (VA), tampa scale of kinesophobia (TSK) and Brief pain inventory (BPI) scores in SCD subjects

| | VA score | TSK | BPI severity score | BPI score interference score | p-value |
|-----------|----------------------------|-----------------------------|----------------------------|------------------------------|---------|
| SS | 2.57±3.09 ₍₁₁₆₎ | 35.73±7.27 ₍₁₁₆₎ | 2.77±2.45 ₍₁₁₆₎ | 3.14±3.09 ₍₁₁₆₎ | 0.000 |
| SC | 2.90±3.01 ₍₄₄₎ | 36.82±8.34 ₍₄₅₎ | 3.49±3.15 ₍₄₄₎ | 4.45±3.15 ₍₄₄₎ | 0.000 |
| SF | 1.00±1.73 ₍₃₎ | 35.75±10.05 ₍₅₎ | 2.43±2.27 ₍₃₎ | 2.67±2.41 ₍₃₎ | 0.000 |

Discussion

The current study presented a novel insight in the relationship between VA, TSK and BPI scores in SCD pain (p-value =0.000).

VAS was informative as it seems to assess the acute clinical change [16] of SCD pain of a patient. However, BPI determined the extent to which SCD pain impacted the patients' daily activities [17] and this was more robust. In SCD, much pain interfered with patient's daily activities such as work, general activity, mood, sleep quality, walking and enjoyment of life. Subjects gave responses that ranged from relatively moderate to severe pain.

An addition of TSK [18] to both VAS and BPI, provided an adjunct pain assessment tool. The Cronbach alpha for TSK analysis assessed internal consistency among the set of questions the subjects responded to. Acceptable reliable range was between 0.6 - 0.7 with a 0.8 or more being very good [19]. Thus, SCD TSK responses seemed reliable. However, a Cronbach alpha ≥ 0.95 seem to indicate redundancy [20]. Subjects experiencing VOC had relatively higher TSK values indicating their fear of movement and establishing SCD hallmark of sudden onset of excruciating musculoskeletal painful episodes.

The study population's general characteristics and age-matched data conformed to the existing literature that SCD subjects were relatively lean [21] and had unique hematological profile [22].

Among the vital signs, heart rate seemed to be elevated in SCD patients experiencing VOC and this is in conformity with suggestions from various authors that heart rate could be a useful marker [23].

Even though temperature of subjects did not seem to be elevated across study subjects, it gave statistical findings during analysis and this calls for further investigation.

Limitations

- There was selection bias since the study involved subjects who underwent medical checkups in a single referral medical institution. A diverse cohort is needed.
- There was recall bias since subjects were inherently aware of their health behaviors. This may have affected the accuracy of the clinical data taken from subjects.

Conclusion

There was an association between BPI, VA and TSK with a p-value of 0.000 in SCD subjects. Subjects experiencing VOC seem to experience increased excruciating musculoskeletal painful episodes.

Acknowledgement

The authors duly acknowledge the staff of the Sickle Cell Clinic, Korle-Bu, Accra, Ghana and Medical Biochemistry, Univ. of Ghana Medical School.

Funding disclosure: This work was financed by AGK and EVA.

Benchmark by Ababio Boateng L, and Reeks R

Analysis of results by Ababio, GK and Ababio Boateng L

Medical writing by Ababio, GK and Ababio Boateng L

The authors declare that there is no conflict of interest.

References

1. Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. *Journal of pain and symptom management*. 2010;40(3):416-35.
2. Barakat LP, Patterson CA, Daniel LC, Dampier C. Quality of life among adolescents with sickle cell disease: mediation of pain by internalizing symptoms and parenting stress. *Health and quality of life outcomes*. 2008;6:1-9
3. Toumi ML, Merzoug S, Boulassel MR. Does sickle cell disease have a psychosomatic component? A particular focus on anxiety and depression. *Life sciences*. 2018;210:96-105.
4. Aboagye S, Torto M, Asah-Opoku K, Nuamah MA, Oppong SA, Samba A. Sickle cell education: a survey of antenatal healthcare givers. *The American Journal of Tropical Medicine and Hygiene*. 2019;101(3):684.
5. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. *Nature reviews Disease primers*. 2018;4(1):1-22.
6. Gallagher PG. Anemia in the pediatric patient. *Blood, The Journal of the American Society of Hematology*. 2022;140(6):571-93.
7. Venkatesan V, Srinivasan S, Babu P, Thangavel S. Manipulation of developmental gamma-globin gene expression: an approach for healing hemoglobinopathies. *Molecular and Cellular Biology*. 2021;41(1):e00253-20.
8. Ballas SK, Darbari DS. Review/overview of pain in sickle cell disease. *Complementary Therapies in Medicine*. 2020;49:102327.
9. Sil S, Cohen LL, Bakshi N, Watt A, Hathaway M, Abudulai F, Dampier C. Changes in pain and psychosocial functioning and transition to chronic pain in pediatric sickle cell disease: a cohort follow-up study. *The Clinical journal of pain*. 2020;36(6):463-71.
10. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, Keefe FJ, Mogil JS, Ringkamp M, Sluka KA, Song XJ. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*. 2020;161(9):1976-82.
11. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. *Nature medicine*. 2010;16(11):1248-57.
12. Chiarotto A, Maxwell LJ, Ostelo RW, Boers M, Tugwell P, Terwee CB. Measurement properties of visual analogue scale, numeric rating scale, and pain severity subscale of the brief pain inventory in patients with low back pain: a systematic review. *The journal of pain*. 2019;20(3):245-63.
13. Stanhope J. Brief pain inventory review. *Occupational Medicine*. 2016;66(6):496-7.
14. Velthuis MJ, Van den Bussche E, May AM, Gijzen BC, Nijs S, Vlaeyen JW. Fear of movement in cancer survivors: validation of the Modified Tampa Scale of Kinesiophobia—Fatigue. *Psycho-Oncology*. 2012;21(7):762-70.
15. Ballas SK. More definitions in sickle cell disease: steady state v base line data. *American journal of hematology*. 2012;87(3):338.
16. Ismail AK, Ghafar MA, Shamsuddin NS, Roslan NA, Kaharuddin H, Muhamad NA. The assessment of acute pain in pre-hospital care using verbal numerical rating and visual analogue scales. *The Journal of emergency medicine*. 2015;49(3):287-93.
17. van Tuijn CF, Sins JW, Fijnvandraat K, Biemond BJ. Daily pain in adults with sickle cell disease—a different perspective. *American journal of hematology*. 2017;92(2):179-86.
18. Ababio GK, Acquaye J, Ekem I, Aleksenko L and Quaye IK. Variation in Pain and Clinical Indices among Patients with Sickle Cell Disease in Ghana. *J Blood Disord*. 2016;3(1): 1037.
19. Hajjar, S. T. Statistical analysis: Internal-consistency reliability and construct validity. *International Journal of Quantitative and Qualitative Research Methods*. 2018; 6(1), 27-38.
20. Hulin, C., & Cudeck, R. Cronbach's alpha on two-item scales. *Journal of Consumer Psychology*. 2001;10(1/2), 55.
21. Moheeb H, Wali YA, El-Sayed MS. Physical fitness indices and anthropometrics profiles in schoolchildren with sickle cell trait/disease. *American journal of hematology*. 2007;82(2):91-7.

22. Behera SK, Kar S, Kar M. Haematological profile of sickle cell patients attending tertiary health care centre of southern Odisha: a cross - sectional study. *International Journal of Research in Medical Sciences*. 2020 Jan;8(1):170.
23. Adebisi, A., Oyebowale, O., Olaniyi, A., & Falase, A. (2019). Heart rate variability study in adult Nigerian subjects with sickle cell disease during vaso-occlusive crisis. *Nigerian Postgraduate Medical Journal*. 2019;26(1), 8.